
Diane Mapes
Articles
-
Jan 10, 2025 |
fredhutch.org | Diane Mapes |Robert Hood
She also gave much of herself — not just to Fred Hutch and Cierra Sisters — but to other nonprofits and organizations, as well as her vast community network, which stretched well beyond the Pacific Northwest. It was not unusual for Hempstead, who lived in south Seattle, to hop on a cross-country flight to help a newly diagnosed friend of a friend, someone she’d never met, get the care they needed. But her advocacy efforts on behalf of underserved cancer patients weren’t just local. Or national.
-
Jan 9, 2025 |
fredhutch.org | Diane Mapes
Nurse navigators help to streamline the process, Wagner said, making sure patients receive all the necessary testing and connect with all the proper clinicians. It’s a concept the organization first used at Fred Hutch at UW Medical Center – Northwest more than five years ago. “We started with nurse navigation for breast cancer patients in 2017,” Wagner said.
-
Oct 14, 2024 |
fredhutch.org | Diane Mapes
Lobular tends to grow in lines, not lumps, thanks to a lack of a “cellular glue” known as E-cadherin, which is encoded by the CDH1 gene. Its web-like growth pattern makes it harder to find on physical exams and mammograms, especially in patients with dense breast tissue. “Many patients are unaware that ILC is hard to see on imaging,” said patient advocate Claire Turner, cofounder of Lobular Breast Cancer UK.
-
Jul 2, 2024 |
fredhutch.org | Diane Mapes
Last Thursday, a tenacious “mom in tennis shoes” who went on to become Chair of the U.S. Senate’s powerful Appropriations Committee stopped by Fred Hutch Cancer Center for an update on its women’s health research. Sen. Patty Murray, senior Democratic senator from Washington state, toured labs and clinics, met scientists young and old, and learned about a new experimental therapy designed to prevent metastatic breast cancer.
-
Jun 28, 2024 |
fredhutch.org | Diane Mapes
A few months back, good news hit the multiple myeloma community: the U.S. Food & Drug Administration voted to accept a new endpoint — MRD, or measurable residual disease — for accelerated approval of treatments for this cancer. What does this mean for myeloma patients? Everything, per Fred Hutch Cancer Center hematologist-oncologist Rahul Banerjee, MD, who treats patients diagnosed with this slow-growing cancer of plasma cells.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →